The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

Exclusion Criteria

• •Any other primary headache disorder according to the International Classification of Headache Disorders except for tension-type headache
• •Any secondary headache disorder according to the International Classification of Headache Disorders
• •Migraine attack during the preceding 48 hours on provocation day
• •Headache during the preceding 24 hours on provocation day
• •Treatment with monoclonal antibodies or participation in clinical trials with monoclonal antibodies during the preceding year
• •Daily consumption of any other drug/medication than oral contraception (birth control)
• •Consumption of any other drug/medication later than four times the plasma half-time of the drug on provocation day except for oral contraception
• •Pregnant or active breastfeeding participants
• •Any cardiovascular diseases including cerebrovascular disorders
• •Information in patient history or during physical examination indicating psychiatric disorders or substance abuse
• •Information in patient history or during physical examination that the screening physician deems relevant for participation in the study